- Home
- BHE vs NAMS Comparison
BHE vs NAMS Comparison
Compare BHE & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BHE | NAMS |
|---|---|---|
| Founded | 1979 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 1996 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BHE | NAMS |
|---|---|---|
| Price | $59.74 | $18.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 16 |
| Target Price | ★ $86.00 | $50.09 |
| AVG Volume (30 Days) | 375.9K | ★ 1.5M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | N/A | ★ 32.81 |
| EPS | ★ 1.38 | N/A |
| Revenue | ★ $2,659,108,000.00 | $22,503,000.00 |
| Revenue This Year | $14.90 | $30.15 |
| Revenue Next Year | $7.76 | $384.12 |
| P/E Ratio | $47.29 | ★ N/A |
| Revenue Growth | ★ 0.11 | N/A |
| 52 Week Low | $41.69 | $19.13 |
| 52 Week High | $100.41 | $42.21 |
Technical Indicators
Market Signals| Indicator | BHE | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 36.06 | 46.07 |
| Support Level | $65.09 | $19.36 |
| Resistance Level | $87.58 | $22.29 |
| Average True Range (ATR) | 2.93 | 1.26 |
| MACD | -0.27 | 0.09 |
| Stochastic Oscillator | 12.37 | 47.15 |
Price Performance
Historical ComparisonAbout BHE Benchmark Electronics Inc.
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia, and Europe, of which key revenue is derived from the Americas.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.